Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell surface antigen CD52
- Molecular classification
- Glycoprotein, Cell surface antigen
01
Overview
CD52 is a small, highly glycosylated protein anchored to the cell membrane via a GPI linkage. It is highly expressed on mature lymphocytes (T cells and B cells), monocytes, dendritic cells, and spermatozoa. It functions in immune regulation, possibly through interactions with Siglec-10 and by modulating calcium signaling. It is a target for alemtuzumab, an antibody used to deplete lymphocytes in the treatment of certain leukemias, lymphomas, and multiple sclerosis.
- Other names
- CAMPATH-1 antigenCluster of Differentiation 52CDW52EDDM5HE5
02
Mechanism of action
Alemtuzumab mediates complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, leading to lymphocyte depletion.
03
Biological functions
Immune regulationAntiadhesionPositive regulation of cytosolic calcium ion concentrationT cell activationB cell activationSiglec-10 binding
04
Disease associations
Lymphoproliferative disordersMultiple sclerosisListeria meningitis
05
Safety considerations
LymphopeniaIncreased risk of infectionInfusion-related reactions
06
Interacting drugs
Alemtuzumab
Beyond the preview
Go deeper on T cell surface antigen CD52.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on T cell surface antigen CD52.